GILD vs NMRK · P/E 18, rev $7.80B vs P/E 33, rev $1.73B
Gilead Sciences Inc (GILD) versus Newmark Group Inc (NMRK) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Newmark Group Inc (NMRK) is a real estate services company listed on US.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported NMRK revenue for 2026-06-30 was $1.73B. Net income was $34.1M. NMRK currently screens at market cap $3.08B and trailing P/E 33.1.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. NMRK currently screens at market cap $3.08B and trailing P/E 33.1.
Not investment advice. Open the GILD and NMRK stock pages for the full models.
Not investment advice.